Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 + Anlotinib in Advanced Esophageal Squamous Cell Cancer
NCT04797507Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
camrelizumabanlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04797507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797507.